Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Related Posts

Factbox-Key economic targets expected to be approved by China's parliament

Factbox-Key economic targets expected to be approved by...

President Prabowo Inaugurates Pegadaian Gold Bank Service, BRI Group Optimistic in Strengthening the National Economy

President Prabowo Inaugurates Pegadaian Gold Bank Servi...

‘She’s not working outside the home’: My mother, 63, inherited $100,000. Is she too old to invest in the stock market?

‘She’s not working outside the home’: My mother, 63, in...

Oil heads for first monthly drop since November as economic uncertainty weighs

Oil heads for first monthly drop since November as econ...

Dollar firms as Trump's tariffs loom, yen set for monthly gain

Dollar firms as Trump's tariffs loom, yen set for month...

Nvidia’s stock is in a funk. Earnings didn’t help, but here’s what could.

Nvidia’s stock is in a funk. Earnings didn’t help, but ...